Telisotuzumab adizutecan (Temab-A; ABBV-400) c-Met–targeted topo-1 ADC posts 37% ORR in platinum-resistant ovarian cancer

Telisotuzumab adizutecan (Temab-A; ABBV-400) is a c-Met protein–targeting antibody–drug conjugate delivering a topoisomerase 1 inhibitor payload; in this Phase 1 open-label basket cohort (NCT06084481), patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer received 2.4mg/kg Q3W after ≥1 to ≤5 prior systemic lines (n=41; median 3 prior lines). At the September 11, 2025 cutoff (median follow-up 5.1 months), confirmed ORR was 37% (15/41; 95% CI 22–53) with a clinical benefit rate of 85% (95% CI 71–94); DOR/PFS/OS were immature, but the ORR is above the typical ~10–20% range seen with single-agent non-platinum chemotherapy options like PLD or topotecan in PROC. Safety was primarily hematologic/GI: any-grade anemia 59%, nausea 59%, fatigue 39%; Grade ≥3 anemia 34%, neutrophils decreased 17%, WBC decreased 15%; adjudicated ILD/pneumonitis was 5% (Grade 1 only), with discontinuation 5%, interruption 39%, and dose reduction 37%—a meaningful dose-modification burden that could matter in a frail, heavily pretreated population.